Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, et al.
Blood (2022) Vol. 140, Iss. 11, pp. 1200-1228
Open Access | Times Cited: 1596

Showing 51-75 of 1596 citing articles:

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients
Naseema Gangat, Omer Karrar, Moazah Iftikhar, et al.
American Journal of Hematology (2023) Vol. 99, Iss. 2, pp. 193-202
Open Access | Times Cited: 35
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia
Brunangelo Falini, Maria Paola Martelli
American Journal of Hematology (2023) Vol. 98, Iss. 3, pp. 481-492
Closed Access | Times Cited: 34
How I Treat AML in 2023 Incorporating the Updated Classifications and Guidelines
Firas El Chaer, Christopher S. Hourigan, Amer M. Zeidan
Blood (2023)
Open Access | Times Cited: 33
The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action
Francesca Fioredda, Julia Skokowa, Hannah Tamary, et al.
HemaSphere (2023) Vol. 7, Iss. 4, pp. e872-e872
Open Access | Times Cited: 30
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial
Amer M. Zeidan, Kiyoshi Ando, Odile Beyne Rauzy, et al.
The Lancet Haematology (2023) Vol. 11, Iss. 1, pp. e38-e50
Closed Access | Times Cited: 30
JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management
Naseema Gangat, Natasha Szuber, Ayalew Tefferi
American Journal of Hematology (2023) Vol. 98, Iss. 6, pp. 965-981
Open Access | Times Cited: 29
Hereditary platelet disorders associated with germ line variants in RUNX1, ETV6, and ANKRD26
Claire C. Homan, Hamish S. Scott, Anna Brown
Blood (2023) Vol. 141, Iss. 13, pp. 1533-1543
Open Access | Times Cited: 28
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants
Álex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 11, pp. 1780-1790
Closed Access | Times Cited: 26
Optical Genome Mapping for Cytogenetic Diagnostics in AML
Verena Nilius‐Eliliwi, Wanda M. Gerding, Roland Schroers, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1684-1684
Open Access | Times Cited: 25
Avapritinib versus Placebo in Indolent Systemic Mastocytosis
Jason Gotlib, Mariana Castells, Hanneke Oude Elberink, et al.
NEJM Evidence (2023) Vol. 2, Iss. 6
Open Access | Times Cited: 25
The international consensus classification of eosinophilic disorders and systemic mastocytosis
Sa A. Wang, Attilio Orazi, Jason Gotlib, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 8, pp. 1286-1306
Closed Access | Times Cited: 25
French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes
Matthieu Groh, Julien Rohmer, Nicolas Etienne, et al.
Orphanet Journal of Rare Diseases (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 24
Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
Nikolaus Jahn, Maral Saadati, Pierre Fenaux, et al.
Leukemia (2023) Vol. 37, Iss. 11, pp. 2187-2196
Open Access | Times Cited: 24
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes
Gonzalo Carreño‐Tarragona, Alberto Álvarez‐Larrán, Claire Harrison, et al.
Blood Advances (2023) Vol. 7, Iss. 9, pp. 1672-1681
Open Access | Times Cited: 23
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia
Min‐Yen Lo, Cheng‐Hong Tsai, Chien‐Chin Lin, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 5, pp. 760-769
Closed Access | Times Cited: 23
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms
Mithun Vinod Shah, Elizabeth Ngoc Hoa Tran, Syed Shah, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 23
Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm
Ayalew Tefferi, Hassan B. Alkhateeb, Naseema Gangat
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 23
Diagnosis and classification of myelodysplastic syndromes
Robert P. Hasserjian, Ulrich Germing, Luca Malcovati
Blood (2023) Vol. 142, Iss. 26, pp. 2247-2257
Closed Access | Times Cited: 23
How I treat transplant-eligible patients with myelofibrosis
Nicolaus Kröger, Christine Wolschke, Nico Gagelmann
Blood (2023) Vol. 142, Iss. 20, pp. 1683-1696
Closed Access | Times Cited: 22
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management
William Shomali, Jason Gotlib
American Journal of Hematology (2024) Vol. 99, Iss. 5, pp. 946-968
Open Access | Times Cited: 14
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes
Maria Sirenko, Elsa Bernard, Maria Creignou, et al.
Blood (2024) Vol. 144, Iss. 11, pp. 1221-1229
Closed Access | Times Cited: 14
TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates
Valeria Santini, Maximilian Stahl, David A. Sallman
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 14
A framework for the clinical implementation of optical genome mapping in hematologic malignancies
Brynn Levy, Rashmi Kanagal‐Shamanna, Nikhil Sahajpal, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 642-661
Open Access | Times Cited: 13
Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms—a Danish longitudinal study
Morten Kranker Larsen, Vibe Skov, Lasse Kjær, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 13
Prognostic impact of CEBPA mutational subgroups in adult AML
Julia-Annabell Georgi, Sebastian Stasik, Michael Krämer, et al.
Leukemia (2024) Vol. 38, Iss. 2, pp. 281-290
Open Access | Times Cited: 12

Scroll to top